Drug Information
| Drug General Information | |||||
|---|---|---|---|---|---|
| Drug ID |
D07RMX
|
||||
| Former ID |
DCL000267
|
||||
| Drug Name |
ZK-thiazolidinone
|
||||
| Drug Type |
Small molecular drug
|
||||
| Indication | Cancer [ICD9: 140-229; ICD10:C00-C96] | Preclinical | [544035] | ||
| Therapeutic Class |
Anticancer Agents
|
||||
| Company |
Bayer Schering Pharma.
|
||||
| Structure |
|
Download2D MOL |
|||
| Formula |
C25H39N10Na15O37P10
|
||||
| Canonical SMILES |
C1=CN(C=N1)CC(O)(P(=O)(O)[O-])P(=O)([O-])[O-].C1=CN(C=N<br />1)CC(O)(P(=O)(O)[O-])P(=O)([O-])[O-].C1=CN(C=N1)CC(O)(P<br />(=O)(O)[O-])P(=O)([O-])[O-].C1=CN(C=N1)CC(O)(P(=O)(O)[O<br />-])P(=O)([O-])[O-].C1=CN(C=N1)CC(O)(P(=O)(O)[O-])P(=O)(<br />[O-])[O-].O.O.[Na+].[Na+].[Na+].[Na+].[Na+].[Na+].[Na+]<br />.[Na+].[Na+].[Na+].[Na+].[Na+].[Na+].[Na+].[Na+]
|
||||
| InChI |
1S/5C5H10N2O7P2.15Na.2H2O/c5*8-5(15(9,10)11,16(12,13)14)3-7-2-1-6-4-7;;;;;;;;;;;;;;;;;/h5*1-2,4,8H,3H2,(H2,9,10,11)(H2,12,13,14);;;;;;;;;;;;;;;;2*1H2/q;;;;;15*+1;;/p-15
|
||||
| InChIKey |
HYMYRPXSMHJPGD-UHFFFAOYSA-A
|
||||
| CAS Number |
CAS 165800-08-8
|
||||
| PubChem Compound ID | |||||
| PubChem Substance ID | |||||
| Target and Pathway | |||||
| Target(s) | Serine/threonine-protein kinase PLK1 | Target Info | Inhibitor | [536464], [537386] | |
| Reactome | Polo-like kinase mediated events | ||||
| Golgi Cisternae Pericentriolar Stack Reorganization | |||||
| APC/C:Cdh1 mediated degradation of Cdc20 and other APC/C:Cdh1 targeted proteins in late mitosis/early G1 | |||||
| Phosphorylation of the APC/C | |||||
| Phosphorylation of Emi1 | |||||
| Condensation of Prophase Chromosomes | |||||
| Separation of Sister Chromatids | |||||
| Resolution of Sister Chromatid Cohesion | |||||
| Regulation of PLK1 Activity at G2/M Transition | |||||
| Activation of NIMA Kinases NEK9, NEK6, NEK7 | |||||
| Loss of Nlp from mitotic centrosomes | |||||
| Recruitment of mitotic centrosome proteins and complexes | |||||
| Loss of proteins required for interphase microtubule organization?from the centrosome | |||||
| Anchoring of the basal body to the plasma membrane | |||||
| RHO GTPases Activate Formins | |||||
| Mitotic Prometaphase | |||||
| Cyclin A/B1 associated events during G2/M transition | |||||
| WikiPathways | Mitotic Telophase/Cytokinesis | ||||
| Mitotic Metaphase and Anaphase | |||||
| Mitotic Prophase | |||||
| Mitotic Prometaphase | |||||
| Integrated Pancreatic Cancer Pathway | |||||
| TNF alpha Signaling Pathway | |||||
| Prostate Cancer | |||||
| miR-targeted genes in muscle cell - TarBase | |||||
| miR-targeted genes in lymphocytes - TarBase | |||||
| miR-targeted genes in epithelium - TarBase | |||||
| Integrated Breast Cancer Pathway | |||||
| Integrated Cancer pathway | |||||
| Mitotic G2-G2/M phases | |||||
| Cell Cycle | |||||
| APC/C-mediated degradation of cell cycle proteins | |||||
| Regulation of toll-like receptor signaling pathway | |||||
| References | |||||
| Ref 536464 | Use of the novel Plk1 inhibitor ZK-thiazolidinone to elucidate functions of Plk1 in early and late stages of mitosis. Mol Biol Cell. 2007 Oct;18(10):4024-36. Epub 2007 Aug 1. | ||||
| Ref 537386 | Polo-like kinase (PLK) inhibitors in preclinical and early clinical development in oncology. Oncologist. 2009 Jun;14(6):559-70. Epub 2009 May 27. | ||||
If You Find Any Error in Data or Bug in Web Service, Please Kindly Report It to Dr. Zhou and Dr. Zhang.